Advanced Circulatory

Advanced Circulatory is the pioneer of a novel therapy platform, called Intrathoracic Pressure Regulation (IPR), which provides Perfusion On Demand and has far-reaching implications for multiple medical conditions. This non-invasive therapy increases circulation, protecting the heart, brain and other vital organs when blood flow is compromised, giving rescuers, clinicians and caregivers the potential to return patients to a full life after critical medical emergencies. Intrathoracic Pressure Regulation (IPR) Therapy enhances the circulatory system's ability to move more blood to and from vital organs when a patient is in crisis. The therapy regulates intrathoracic pressure in the chest to reduce intracranial pressure and maximize the blood drawn into and pushed out of the heart with each heartbeat (if the patient has a pulse), or with each chest compression if the patient is receiving cardiopulmonary resuscitation (CPR). Our therapy is delivered through non-invasive devices called impedance threshold devices, or ITDs, which regulate airflow into the lungs. The ResQPOD® Impedance Threshold Device is for use both inside and outside the hospital to optimize circulation for cardiac arrest patients during the administration of CPR. The ResQGARD® Impedance Threshold Device is for use in spontaneously breathing patients with poor perfusion. The generally cleared indication for impedance threshold devices available for sale in the United States is for a temporary increase in blood circulation during emergency care, hospital, clinical and home use. Research is ongoing in the United States to evaluate the long-term benefit of ITDs for specific indications. The studies listed here are not intended to imply specific outcomes-based claims not yet cleared by the US FDA. For additional information, please visit: http://advancedcirculatory.com/products/resqpod-itd/resqpod-itd-research-2/ and http://advancedcirculatory.com/products/resqgard-itd/resqgard-research/

• Employees 6
• Founded 1997
• Annual Revenue $16275000